Fresenius Kabi Usa Company Profile
✉ Email this page to a colleague
What is the competitive landscape for FRESENIUS KABI USA, and when can generic versions of FRESENIUS KABI USA drugs launch?
FRESENIUS KABI USA has three hundred and one approved drugs.
There are twenty-three US patents protecting FRESENIUS KABI USA drugs. There are two tentative approvals on FRESENIUS KABI USA drugs.
There are one hundred and twenty-nine patent family members on FRESENIUS KABI USA drugs in twenty-five countries and four hundred and sixty-two supplementary protection certificates in seventeen countries.
Summary for Fresenius Kabi Usa
International Patents: | 129 |
US Patents: | 23 |
Tradenames: | 247 |
Ingredients: | 184 |
NDAs: | 301 |
Patent Litigation for Fresenius Kabi Usa: | See patent lawsuits for Fresenius Kabi Usa |
PTAB Cases with Fresenius Kabi Usa as petitioner: | See PTAB cases with Fresenius Kabi Usa as petitioner |
PTAB Cases with Fresenius Kabi Usa as patent owner: | See PTAB cases with Fresenius Kabi Usa as patent owner |
Drugs and US Patents for Fresenius Kabi Usa
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Fresenius Kabi Usa | SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER | sodium chloride | INJECTABLE;INJECTION | 207310-001 | Sep 19, 2017 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Fresenius Kabi Usa | MAGNESIUM SULFATE IN PLASTIC CONTAINER | magnesium sulfate | INJECTABLE;INJECTION | 206485-001 | Mar 15, 2016 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Fresenius Kabi Usa | NESACAINE-MPF | chloroprocaine hydrochloride | INJECTABLE;INJECTION | 009435-004 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Fresenius Kabi Usa
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Fresenius Kabi Usa | NAROPIN | ropivacaine hydrochloride | SOLUTION;INJECTION | 020533-005 | Sep 24, 1996 | 4,695,576 | ⤷ Try a Trial |
Fresenius Kabi Usa | NAROPIN | ropivacaine hydrochloride | SOLUTION;INJECTION | 020533-003 | May 1, 1998 | 5,834,489 | ⤷ Try a Trial |
Fresenius Kabi Usa | DILAUDID-HP | hydromorphone hydrochloride | INJECTABLE;INJECTION | 019034-002 | Aug 4, 1994 | 6,589,960 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for FRESENIUS KABI USA drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Injection | 2 mg/mL | ➤ Subscribe | 2011-06-22 |
➤ Subscribe | Injection | 10 mg/mL | ➤ Subscribe | 2011-11-04 |
➤ Subscribe | for Injection | 200 mcg/vial | ➤ Subscribe | 2015-05-01 |
➤ Subscribe | Injection | 2 mg/mL, 100 mL | ➤ Subscribe | 2015-01-30 |
➤ Subscribe | Injection | 100 mg/mL, 2.5 mL vials | ➤ Subscribe | 2007-09-24 |
➤ Subscribe | Oral Solution | 5 mg/5mL | ➤ Subscribe | 2011-02-25 |
➤ Subscribe | Tablets | 2 mg, 4 mg, and 8 mg | ➤ Subscribe | 2013-08-05 |
➤ Subscribe | for Injection | 100 mcg/vial and 500 mcg/vial | ➤ Subscribe | 2015-04-14 |
➤ Subscribe | Injection | 2 mg/mL, 5 mg/mL and 10 mg/mL, 20 mL, 30 mL and 20 mL vials | ➤ Subscribe | 2006-11-13 |
➤ Subscribe | Injection | 2 mg/mL, 200 mL | ➤ Subscribe | 2015-09-03 |
➤ Subscribe | Injection | 1 mg/mL, 50 mL vials | ➤ Subscribe | 2011-12-16 |
International Patents for Fresenius Kabi Usa Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Portugal | 1507502 | ⤷ Try a Trial |
Japan | 2016512455 | ⤷ Try a Trial |
China | 100398084 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Fresenius Kabi Usa Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2822954 | 1890030-8 | Sweden | ⤷ Try a Trial | PRODUCT NAME: BICTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BICTEGRAVIR SODIUM; REG. NO/DATE: EU/1/18/1289 20180625 |
1853250 | 37/2014 | Austria | ⤷ Try a Trial | PRODUCT NAME: PACLITAXEL, DAS ALS ALBUMIN GEBUNDENE NANOPARTIKEL FORMUIERT IST.; REGISTRATION NO/DATE: EU/1/07/428 (MITTEILUNG) (GEAENDERT DURCH C(2013) 9835) 20131230 |
0383579 | 97C0029 | Belgium | ⤷ Try a Trial | PRODUCT NAME: REMIFENTANILUM HYDROCHLORIDUM (= REMIFENTANILUM BASIS); NAT. REGISTRATION NO/DATE: 725 IS 146 F 12 19970408; FIRST REGISTRATION: DE 36.335.00.00 19960517 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.